BridgeBio shares rose 2.10% to $69.41 after Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showed broad efficacy and placebo-matched safety. The company plans a U.S. FDA filing in H1 2026.
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
Diagnosing rare diseases can take 3 to 15 years, while about 95% lack approved treatments. Families are advocating for regulatory changes to speed access to therapies as new digital tools aim to improve clinical trials.
YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.
AI systems are evolving into essential research collaborators in 2026, while quantum computing emerges as a transformative technology with potential to create $200-500 billion in value for life sciences by 2035.
Tozaro, a Bedfordshire-based biotech company, has raised £6 million in funding led by Mercia Ventures to advance its Smart Polymer technology aimed at reducing the high production costs of cell and gene therapies.
BridgeBio Pharma announced positive Phase 3 topline results for infigratinib in children with achondroplasia, meeting primary and key secondary endpoints. The company plans regulatory submissions in the U.S. and Europe in the second half of 2026.
BridgeBio Pharma announced positive Phase 3 topline results for infigratinib in children with achondroplasia, meeting primary and key secondary endpoints. The company plans regulatory submissions in the U.S. and Europe in the second half of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587242 |
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping |
NOT_YET_RECRUITING | PHASE3 |
| NCT07486752 |
BAG3-DCM Natural History Study |
NOT_YET_RECRUITING | |
| NCT06762002 |
Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort |
RECRUITING | |
| NCT06644742 |
PKP2-ACM Natural History Study |
RECRUITING | |
| NCT06260319 |
Decoding Developmental Disorders in Humams |
COMPLETED | |
| NCT06235580 |
Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions |
RECRUITING | |
| NCT03984266 |
The Pilot Study of High-throughput Sequencing in Neonatal Birth Defects |
COMPLETED | |
| NCT03385876 |
Rapid Whole Genome Sequencing Study |
ENROLLING_BY_INVITATION | NA |
| NCT03211039 |
Perinatal Precision Medicine |
ACTIVE_NOT_RECRUITING | NA |
| NCT02917460 |
Rady Children's Institute Genomic Biorepository |
RECRUITING | NA |
